abstract |
The application provides a polypeptide comprising the sequence SLMTNLAAL, Ser 13 to Leu 21 of amino acid sequence shown in Figure 1 or SEQ ID No 1, and having HLA-A2 haplotype binding activity, or a polynucleotide encoding said polypeptide. Vaccines containing the polypeptide or polynucleotides encoding the polypeptide are also provided. |